Piramal Pharma moves to take full ownership of Yapan Bio

The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion

Piramal Pharma is moving towards full ownership of Yapan Bio. It has exercised its call option to acquire the remaining 26 per cent stake in the company.

The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion. The decision has been approved by the Administrative Committee of the Board of Directors.

Yapan Bio provides process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.

Piramal Pharma is in talks with the existing shareholders to complete the acquisition. The deal value and share transfer date are yet to be finalised.

M&Apharma CDMOPiramal PharmaYapan Bio
Comments (0)
Add Comment